Prof. Upender Manne

University of Alabama at Birmingham, USA

Email: [email protected]

Qualifications

1987 Ph.D., Osmania University, India

1983 M.Sc., Osmania University, India

Publications (selected)

1. Afaq, F., Pathi, S.S., Chakravarthi, B.V.S.K., Chandrashekar, D.S., Carskadon, S. and others. AAA ATPase TRIP13 is overexpressed in prostate cancer and promotes tumor progression. Translational Oncology, 68, 102743, 2026.
2. Kumar, R., Shahrokhi, G., Shaikh, S., Negedu, S., He, N., Yates, C.C., Manne, U. and others. Metatranscriptomic signatures in triple negative breast cancer. Cancer Research, 86(7_Supplement), 3258, 2026.
3. Manne, A., Yang, W., Guo, Y., Sahai, V., Bajpai, P., Bao, Y., Khan Niazi, M.K. and others. MUC5AC expression defines an immune-inflamed but functionally restrained tumor microenvironment in pancreatic ductal adenocarcinoma. Cancer Research, 86(7_Supplement), 1043, 2026.
4. Manne, A., Yu, L., Yang, W., Khan Niazi, M.K., Paluri, R., Kasi, A., Bajpai, P. and others. A pre-treatment cfDNA methylation signature linking prognosis and drug-resistance biology in pancreatic ductal adenocarcinoma. Cancer Research, 86(7_Supplement), 1196, 2026.
5. Manne, A., Leya, A., Akbar, A.R., Manne, U., Noonan, A., Kasi, A., Esnakula, A. and others. Deploying artificial intelligence driven digital pathology for real world clinical decision-making in pancreatic cancer. Cancer Research, 86(7_Supplement), 2743, 2026.
6. Karthikeyan, S.K., Chandrashekar, D.S., Sahai, S., Shrestha, S., Aneja, R. and others. MammOnc-DB, an integrative breast cancer data analysis platform for target discovery. NPJ Breast Cancer, 11(1), 35, 2025.
7. Piazza, G.A., Bandi, D.S.R., Nagaraju, G.P., Berry, K., Wang, J., Ramesh, S. and others. A 1st in class pan-RAS inhibitor with robust antitumor activity in PDAC models and advantages over other RAS inhibitors to escape resistance. Proc. Am. Assoc. Cancer Res. Annu. Meet, 85, 4392, 2025.
8. Manne, A., Bao, Y., Sheel, A., Sara, A., Manne, U., Thanikachalam, K. and others. Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights. Frontiers in Oncology, 15, 1544928, 2025.
9. Bandi, D.S.R., Nagaraju, G.P., Sarvesh, S., Carstens, J.L., Foote, J.B., Graff, E.C. and others. ADT-1004: A first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma. Molecular Cancer, 24(1), 76, 2025.
10. Varambally, S., Rubey, D., Chandrashekar, D.S., Shovon, A.R., Chand Puli, G. and others. Abstract A019: UALCAN Mobile app, an update to the cancer multi-omic data analysis application. Cancer Research, 85(5_Supplement), A019, 2025.
11. Chandrashekar, D.S., Afaq, F., Karthikeyan, S.K., Athar, M., Shrestha, S., Singh, R. and others. Bromodomain inhibitor treatment leads to overexpression of multiple kinases in cancer cells. Neoplasia, 57, 101046, 2024.
12. Saurav, S., Karfa, S., Vu, T., Liu, Z., Datta, A., Manne, U., Samuel, T. and Datta, P.K. Overcoming irinotecan resistance by targeting its downstream signaling pathways in colon cancer. Cancers, 16(20), 3491, 2024.
13. Reddy Bandi, D.S., Nagaraju, G.P., Sarvesh, S., Carstens, J.L., Foote, J.B. and others. ADT-1004: a first-in-class, orally bioavailable selective pan-RAS inhibitor for pancreatic ductal adenocarcinoma. bioRxiv, 2024.
14. Bandi, D.S.R., Nagaraju, G.P., Foote, J.B., Keeton, A., Chen, X., Berry, K.L. and others. 127 (PB115): Survival benefit and tumor regression with a dual RAS/β-catenin inhibitor, ADT-030, in murine models of pancreatic and lung cancer. European Journal of Cancer, 211, 2024.
15. Bandi, D.S.R., Nagaraju, G.P., Foote, J.B., Keeton, A., Chen, X., Berry, K.L. and others. 133 (PB121): A novel pan-RAS inhibitor (ADT-1004) with superior efficacy over mutation-specific KRAS inhibitors in mouse models of pancreatic cancer. European Journal of Cancer, 211, 2024.
16. Paluri, R.K., Haris, H., Li, P., Gbolahan, O., Jacob, R. and Manne, U. Role of chemoradiation in gallbladder cancer—a single institution retrospective analysis. Journal of Gastrointestinal Oncology, 14(5):2212, 2023.
17. Yamada, H.Y., Xu, C., Jones, K.L., O’Neill, P.H., Venkateshwar, M., Chiliveru, S. and others. Molecular disparities in colorectal cancers of white americans, alabama african americans, and oklahoma american indians. NPJ Precision Oncology, 7(1), 79, 2023.
18. Agarwal, S., Afaq, F., Bajpai, P., Behring, M., Kim, H.G., Varambally, A. and others. BZW2 inhibition reduces colorectal cancer growth and metastasis. Molecular Cancer Research, 21(7):698-712, 2023.
19. Zimmer, K., Kocher, F., Untergasser, G., Kircher, B., Amann, A., Baca, Y., Xiu, J. and others. PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system. NPJ Precision Oncology, 7(1), 64, 2023.
20. Elkholy, A., Avuthu, N., Abdalla, M., Behring, M., Bajpai, P., Kim, H.G., Header, D. and others. Microbiome diversity in African American, European American, and Egyptian colorectal cancer patients. Heliyon, 9(7), 2023.

Personal Details

WoS Researcher ID: DXP-4445-2022

https://scholars.uab.edu/2094-upender-manne

http://scholar.google.com/citations?user=jTOt-wYAAAAJ&hl=en

https://www.researchgate.net/profile/Upender-Manne